Murlidhar Rajagopalan, Arun Inamadar, Asit Mittal, Autar K Miskeen, C R Srinivas, Kabir Sardana, Kiran Godse, Krina Patel, Madhu Rengasamy, Shivaprakash Rudramurthy, Sunil Dogra
{"title":"关于印度皮肤癣管理的专家共识(ECTODERM India)。","authors":"Murlidhar Rajagopalan, Arun Inamadar, Asit Mittal, Autar K Miskeen, C R Srinivas, Kabir Sardana, Kiran Godse, Krina Patel, Madhu Rengasamy, Shivaprakash Rudramurthy, Sunil Dogra","doi":"10.1186/s12895-018-0073-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Dermatophytosis management has become an important public health issue, with a large void in research in the area of disease pathophysiology and management. Current treatment recommendations appear to lose their relevance in the current clinical scenario. The objective of the current consensus was to provide an experience-driven approach regarding the diagnosis and management of tinea corporis, cruris and pedis.</p><p><strong>Methods: </strong>Eleven experts in the field of clinical dermatology and mycology participated in the modified Delphi process consisting of two workshops and five rounds of questionnaires, elaborating definitions, diagnosis and management. Panel members were asked to mark \"agree\" or \"disagree\" beside each statement, and provide comments. More than 75% of concordance in response was set to reach the consensus.</p><p><strong>Result: </strong>KOH mount microscopy was recommended as a point of care testing. Fungal culture was recommended in chronic, recurrent, relapse, recalcitrant and multisite tinea cases. Topical monotherapy was recommended for naïve tinea cruris and corporis (localised) cases, while a combination of systemic and topical antifungals was recommended for naïve and recalcitrant tinea pedis, extensive lesions of corporis and recalcitrant cases of cruris and corporis. Because of the anti-inflammatory, antibacterial and broad spectrum activity, topical azoles should be preferred. Terbinafine and itraconazole should be the preferred systemic drugs. Minimum duration of treatment should be 2-4 weeks in naïve cases and > 4 weeks in recalcitrant cases. Topical corticosteroid use in the clinical practice of tinea management was strongly discouraged.</p><p><strong>Conclusion: </strong>This consensus guideline will help to standardise care, provide guidance on the management, and assist in clinical decision-making for healthcare professionals.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"18 1","pages":"6"},"PeriodicalIF":0.0000,"publicationDate":"2018-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-018-0073-1","citationCount":"137","resultStr":"{\"title\":\"Expert Consensus on The Management of Dermatophytosis in India (ECTODERM India).\",\"authors\":\"Murlidhar Rajagopalan, Arun Inamadar, Asit Mittal, Autar K Miskeen, C R Srinivas, Kabir Sardana, Kiran Godse, Krina Patel, Madhu Rengasamy, Shivaprakash Rudramurthy, Sunil Dogra\",\"doi\":\"10.1186/s12895-018-0073-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Dermatophytosis management has become an important public health issue, with a large void in research in the area of disease pathophysiology and management. Current treatment recommendations appear to lose their relevance in the current clinical scenario. The objective of the current consensus was to provide an experience-driven approach regarding the diagnosis and management of tinea corporis, cruris and pedis.</p><p><strong>Methods: </strong>Eleven experts in the field of clinical dermatology and mycology participated in the modified Delphi process consisting of two workshops and five rounds of questionnaires, elaborating definitions, diagnosis and management. Panel members were asked to mark \\\"agree\\\" or \\\"disagree\\\" beside each statement, and provide comments. More than 75% of concordance in response was set to reach the consensus.</p><p><strong>Result: </strong>KOH mount microscopy was recommended as a point of care testing. Fungal culture was recommended in chronic, recurrent, relapse, recalcitrant and multisite tinea cases. Topical monotherapy was recommended for naïve tinea cruris and corporis (localised) cases, while a combination of systemic and topical antifungals was recommended for naïve and recalcitrant tinea pedis, extensive lesions of corporis and recalcitrant cases of cruris and corporis. Because of the anti-inflammatory, antibacterial and broad spectrum activity, topical azoles should be preferred. Terbinafine and itraconazole should be the preferred systemic drugs. Minimum duration of treatment should be 2-4 weeks in naïve cases and > 4 weeks in recalcitrant cases. Topical corticosteroid use in the clinical practice of tinea management was strongly discouraged.</p><p><strong>Conclusion: </strong>This consensus guideline will help to standardise care, provide guidance on the management, and assist in clinical decision-making for healthcare professionals.</p>\",\"PeriodicalId\":9014,\"journal\":{\"name\":\"BMC Dermatology\",\"volume\":\"18 1\",\"pages\":\"6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1186/s12895-018-0073-1\",\"citationCount\":\"137\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Dermatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s12895-018-0073-1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12895-018-0073-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Expert Consensus on The Management of Dermatophytosis in India (ECTODERM India).
Background: Dermatophytosis management has become an important public health issue, with a large void in research in the area of disease pathophysiology and management. Current treatment recommendations appear to lose their relevance in the current clinical scenario. The objective of the current consensus was to provide an experience-driven approach regarding the diagnosis and management of tinea corporis, cruris and pedis.
Methods: Eleven experts in the field of clinical dermatology and mycology participated in the modified Delphi process consisting of two workshops and five rounds of questionnaires, elaborating definitions, diagnosis and management. Panel members were asked to mark "agree" or "disagree" beside each statement, and provide comments. More than 75% of concordance in response was set to reach the consensus.
Result: KOH mount microscopy was recommended as a point of care testing. Fungal culture was recommended in chronic, recurrent, relapse, recalcitrant and multisite tinea cases. Topical monotherapy was recommended for naïve tinea cruris and corporis (localised) cases, while a combination of systemic and topical antifungals was recommended for naïve and recalcitrant tinea pedis, extensive lesions of corporis and recalcitrant cases of cruris and corporis. Because of the anti-inflammatory, antibacterial and broad spectrum activity, topical azoles should be preferred. Terbinafine and itraconazole should be the preferred systemic drugs. Minimum duration of treatment should be 2-4 weeks in naïve cases and > 4 weeks in recalcitrant cases. Topical corticosteroid use in the clinical practice of tinea management was strongly discouraged.
Conclusion: This consensus guideline will help to standardise care, provide guidance on the management, and assist in clinical decision-making for healthcare professionals.
期刊介绍:
BMC Dermatology is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of skin disorders, as well as related molecular genetics, pathophysiology, and epidemiology. BMC Dermatology (ISSN 1471-5945) is indexed/tracked/covered by PubMed, MEDLINE, CAS, EMBASE, Scopus and Google Scholar.